 |
1 Disease |  |
21 Trials |
|
21 Trials |  |
381 News |  |
| «123456» |
- | Ensacove (ensartinib) / Xcovery, Xalkori (crizotinib) / Pfizer
Journal: Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. (Pubmed Central) - Dec 27, 2022
Consequently, ALK inhibition delayed tumor relapse after chemotherapy in vivo by effectively decreasing the content of PaCSCs. In summary, our results demonstrate that targeting the MDK/PTN-ALK axis with clinically-approved inhibitors impairs in vivo tumorigenicity and chemoresistance in PDAC suggesting a new treatment approach to improve the long-term survival of PDAC patients.
- || Ensacove (ensartinib) / Xcovery
New P1 trial: A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions (clinicaltrials.gov) - Dec 27, 2022
P1, N=32, Not yet recruiting, Sponsor: Xcovery Holding Company, LLC
- | Biomarker, Trial completion date, Trial primary completion date: NRG-LU003: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 7, 2022
P2, N=660, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In summary, our results demonstrate that targeting the MDK/PTN-ALK axis with clinically-approved inhibitors impairs in vivo tumorigenicity and chemoresistance in PDAC suggesting a new treatment approach to improve the long-term survival of PDAC patients. Trial completion date: Dec 2025 --> May 2023 | Trial primary completion date: Dec 2025 --> May 2023
- EFFICACY, SAFETY AND BRAIN METASTASES CONTROL OF FIRST-LINE TREATMENT STRATEGIES FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_8;
Patients received eight different treatments: alectinib (300 mg and 600 mg), brigatinib, ceritinib, crizotinib, ensartinib, lorlatinib, and chemotherapy. In our network meta-analysis, alectinib and lorlatinib resulted the therapeutics with the highest probability to be the best first-line options for ALK-rearranged NSCLC patients ensuring prolonged disease control.
- | Journal, HEOR: Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. (Pubmed Central) - Oct 11, 2022
For Chinese patients with advanced ALK-positive NSCLC, ensartinib was a cost-effective option compared with crizotinib, and was a dominant alternative to ceritinib and brigatinib. Although lorlatinib and alectinib were associated with prolonged survival compared with ensartinib, they were less cost-effective than ensartinib due to the overwhelming total costs.
- | Journal: Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors. (Pubmed Central) - Oct 7, 2022
When this system was applied to repotrectinib and ensartinib, the results suggested that these drugs can be used for the second-line treatment of ALK-positive NSCLC. Predicting resistance mutations against TKIs will provide useful information to aid in the development of effective therapeutic strategies.
- | Ensacove (ensartinib) / Xcovery, Alecensa (alectinib) / Roche
Journal: A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene (Pubmed Central) - Oct 6, 2022
Aletinib was effective for this patient but the patients died on September 30, 2021. This is a report of lung squamous cell carcinoma patients with CLIP1-ALK fusion gene treated with ALK inhibitors..
- || Retrospective data, Review, Journal: ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. (Pubmed Central) - Sep 28, 2022
The limited OS follow-up and inadequate sample sizes might contribute to having no statistically significant difference in OS of lorlatinib versus crizotinib. More high-quality and longer follow-up RCTs are warranted to prove our findings.
- Ensacove (ensartinib) / Xcovery, Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Differentiating Ensartinib from Lorlatinib and Alectinib for first line use in an ALK+ non-small cell lung cancer preclinical model (ResCu) (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_440;
Alectinib led to the most cross-resistance to other ALKi while lorlatinib led to the most cross-resistance to other drug classes in both backgrounds. Biomarkers of ALKi escape and cross-resistance were derived from RNA-seq, and we are currently validating these alterations against clinical samples.
- || Review, Journal: Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC). (Pubmed Central) - Sep 3, 2022
The role for anti-angiogenic therapy in ALK rearranged NSCLC, however, remains to be elucidated. This review will discuss the pre-clinical rationale, clinical trial evidence to date, and future directions to evaluate anti-angiogenic therapy in ALK rearranged NSCLC.
- A Bayesian Network Meta-Analysis of the Tyrosine Kinase Inhibitors (TKI) for ALK-Positive Advanced Non-Small Cell Lung Cancer With or Without Brain Metastasis (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2577;
This review will discuss the pre-clinical rationale, clinical trial evidence to date, and future directions to evaluate anti-angiogenic therapy in ALK rearranged NSCLC. Lorlatinib showed better estimates of efficacy in comparison to the first and second generation TKIs especially in PFS, with its ranking by the front, which can be considered as the best option for clinical treatment.
- || Clinical, Retrospective data, Journal: Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. (Pubmed Central) - Aug 30, 2022
Lorlatinib may have advantageous PFS compared with other agents but a greater risk of severe toxicity. Second-generation inhibitors, including alectinib, brigatinib, and ensartinib, provide major efficacy with less toxicity and remain appropriate regimens in the front-line setting.
- | Ensacove (ensartinib) / Xcovery
Enrollment open: A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2022
P2, N=10, Recruiting, Sponsor: Peking University Cancer Hospital & Institute
Second-generation inhibitors, including alectinib, brigatinib, and ensartinib, provide major efficacy with less toxicity and remain appropriate regimens in the front-line setting. Not yet recruiting --> Recruiting
- |||||| Ensacove (ensartinib) / Xcovery
New trial, Real-world evidence, Real-world, Metastases: A Real World Study of Ensartinib in Advanced ALK-positive NSCLC (clinicaltrials.gov) - Aug 11, 2022
P=N/A, N=490, Recruiting, Sponsor: Peking Union Medical College Hospital
- | Ensacove (ensartinib) / Xcovery, Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation (clinicaltrials.gov) - Aug 8, 2022
P2, N=77, Not yet recruiting, Sponsor: Sun Yat-sen University
- An open-label, prospective, phase II, umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2583;
For mutation-negative patients, PD-L1≥1% will receive Camrelizumab with chemotherapy and PD-L1<1% will receive chemotherapy only...The secondary endpoints include pCR, MPR, EFS, DFS, OS, R0 rate, perioperative outcomes. The exploratory endpoint is to investigate the relationship between oncological prognosis and minimal residual disease (MRD).
- Ensacove (ensartinib) / Xcovery
Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2237;
Conclusions The POP-PK model of ensartinib was successfully developed and validated for the first time. For the indicated patient populations, a 200 mg QD ensartinib starting dose would provide similar efficacy relative to the 225 mg QD starting dose which was recommended in the instruction of ensartinib, but was associated with a decreased rate of rash.
- || Retrospective data, Review, Journal: Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. (Pubmed Central) - Jul 23, 2022
Lorlatinib had a high incidence of hypertriglyceridemia and hypercholesterolemia, which were rarely reported in other ALK inhibitors. The incidences of grade ≥ 3 AEs for individual ALK inhibitor were moderately high yet manageable. Different toxicity spectrums were found in each ALK inhibitor.
- |||||| Ensacove (ensartinib) / Xcovery
Enrollment open: Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 15, 2022
P3, N=202, Recruiting, Sponsor: Betta Pharmaceuticals Co., Ltd.
Different toxicity spectrums were found in each ALK inhibitor. Not yet recruiting --> Recruiting
- | Ensacove (ensartinib) / Xcovery
Journal, HEOR: Cost-effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China. (Pubmed Central) - Jul 2, 2022
In 2021, the per capita GDP of China is US$12,721.33, and the incremental cost utility is lower than the threshold of willingness to pay US$38,163.99. Compared with crizotinib, ensatinib is economical in the treatment of ALK-positive NSCLC and should be promoted.
- Ensacove (ensartinib) / Xcovery, Focus V (anlotinib) / Advenchen, Sino Biopharm, Alecensa (alectinib) / Roche
Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1331;
Plasma levels of ALK resistance mutations correlated well with tumor response assessed by CT scanning, suggesting that non-invasive tumor molecular profiling by NGS would provide effective dynamic monitoring in patients with ALK-positive SCLC. However, the treatment of ALK-TKIs resistance remains to be discussed.
- Ensacove (ensartinib) / Xcovery
Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1115;
We firstly report that one patient with CNS metastases and a novel NBAS-ALK, EML4-ALK double-ALK fusion is sensitive to ensartinib. NSCLC patients with double-ALK fusion may benefit from ensartinib and the NGS could help predict the sensitivity and efficacy of ALK-TKIs.
- Ensacove (ensartinib) / Xcovery
ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3) (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1041;
P2
Under ensartinib pressure, the V1 subtype was more prone to the G1269A mutation, while the V3 subtype was more prone to the G1202R mutation, although there was no significant difference in survival between the two groups. This difference may allow for a more precise selection of later-line therapy.
- | Ensacove (ensartinib) / Xcovery
Journal: Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements. (Pubmed Central) - Jun 14, 2022
This difference may allow for a more precise selection of later-line therapy. No abstract available
- || Alunbrig (brigatinib) / Takeda
Review, Journal: Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. (Pubmed Central) - Jun 11, 2022
The incidence of grade ≥3 AEs was similar between brigatinib and other next-generation ALK inhibitors (except for alectinib), while brigatinib could significantly delay the time to worsening in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status (GHS)/quality of life (QoL) vs. crizotinib (HR: 0.69, 95% CI: 0.49, 0.98). (4) Brigatinib had longer PFS compared to crizotinib and ceritinib and had comparable efficacy and safety profile with other 2nd-generation ALK inhibitors in first-line treatments for patients with ALK-positive non-small-cell lung cancer.
- || Retrospective data, Review: Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. (Pubmed Central) - Jun 4, 2022
Moreover, lorlatinib in never-smokers and low-dose alectinib in smokers could be considered optimal first-line therapy for advanced ALK-positive NSCLC. Acceptable limitations of evidence, such as study risk of bias, inconsistency, and imprecision, were present in this NMA.
- | Alunbrig (brigatinib) / Takeda
Journal: Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. (Pubmed Central) - May 24, 2022
Through a spurious exercise of an indirect comparison with other available 2G ALKi, we tent to summarize the required knowledge to properly choose the best drug at the right time. Furthermore, we reviewed available data on molecular resistance mechanisms and putative therapeutic applications in other contexts, such as ROS1+ NSCLC patients or EGFR+ ones progressing to osimertinib.
- | Ensacove (ensartinib) / Xcovery
New P2 trial: A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 17, 2022
P2, N=10, Not yet recruiting, Sponsor: Beijing Cancer Hospital
- | Ensacove (ensartinib) / Xcovery
Journal: P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells. (Pubmed Central) - May 15, 2022
In conclusion, we report that ensartinib is a substrate of P-gp, and provide evidence that this transporter plays a role in the development of ensartinib resistance. Further investigation is needed.
- | Ensacove (ensartinib) / Xcovery
Journal: Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer (Pubmed Central) - Apr 29, 2022
In order to facilitate clinical application and provide patients with more treatment options, under the guidance of the Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association, this article collects and summarizes the common adverse reactions of ensartinib. Based on the clinical practice, a clear adverse classification and specific treatment plan are formulated, in order to provide a corresponding reference for clinicians to make more comprehensive clinical decisions.
- Xalkori (crizotinib) / Pfizer
Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2990;
There was no significant difference in mPFS and mOS among patients treated with different 2G ALK-TKI. For patients with CNS metastases, treatment with Alectinib and Brigatinib results in higher ORR and PFS.
- || Review, Journal: Targeting ALK Rearrangements in NSCLC: Current State of the Art. (Pubmed Central) - Apr 26, 2022
Recently, a potent, third-generation ALK inhibitor, lorlatinib, has been approved by the Food and Drug Administration (FDA) for the first-line treatment of ALK-positive (ALK+) NSCLC...Efforts have also been undertaken to develop further generations of ALK inhibitors. This review will summarize the current situation of targeting the ALK signaling pathway.
- |||||||||| Ensacove (ensartinib) / Xcovery
New P3 trial: Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 21, 2022
P3, N=202, Not yet recruiting, Sponsor: Betta Pharmaceuticals Co., Ltd.
- | Ensacove (ensartinib) / Betta Pharma
Biomarker, Enrollment open, Metastases: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Apr 11, 2022
P2, N=98, Recruiting, Sponsor: National Cancer Institute (NCI)
This review will summarize the current situation of targeting the ALK signaling pathway. Suspended --> Recruiting
- | Ensacove (ensartinib) / Xcovery, Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical, Journal: First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: State of the art and future development. (Pubmed Central) - Apr 7, 2022
Expert Opinion Alectinib should currently be regarded as the standard of care for the first-line treatment of ALK+ NSCLC, considering its superior efficacy and safety profile. Regarding developing agents, lorlatinib and ensartinib appear to be the most promising ones, even though the data from their trials are still immature.
- | repotrectinib (TPX-0005) / Turning Point Therapeutics, ZAI Lab
Journal: Translational Strategies for Repotrectinib in Neuroblastoma. (Pubmed Central) - Mar 26, 2022
Repotrectinib plus chemotherapy was superior to chemotherapy alone in ALK-mutant and ALK wild-type PDX models. These results demonstrate that repotrectinib has anti-tumor activity in genotypically diverse neuroblastoma models, and that combination of a multi-kinase inhibitor with chemotherapy may be a promising treatment paradigm for translation to the clinic.
- || Ensacove (ensartinib) / Xcovery
Clinical, PK/PD data, Journal: Effects of food on the pharmacokinetics of ensartinib in healthy Chinese subjects. (Pubmed Central) - Mar 26, 2022
The final model included food and age as covariates on apparent distribution and apparent clearance. Based on the final PopPK model, food was identified as a significant covariate for apparent clearance, apparent volume of distribution, and absorption rate constant, consistent with the results of non-compartmental pharmacokinetic analysis.
- || Ensacove (ensartinib) / Xcovery, Xalkori (crizotinib) / Pfizer
Clinical, Journal: Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. (Pubmed Central) - Mar 15, 2022
P3
Ensartinib represents a new first-line option for patients with ALK-positive NSCLC. ClinicalTrials.gov Identifier: NCT02767804.
- | Ensacove (ensartinib) / Xcovery
Journal: Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench. (Pubmed Central) - Mar 12, 2022
ClinicalTrials.gov Identifier: NCT02767804. No abstract available
- || Ensacove (ensartinib) / Xcovery, Xalkori (crizotinib) / Pfizer
Review, Journal, IO biomarker: Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. (Pubmed Central) - Mar 11, 2022
Following the development of crizotinib, the first ALK-TKI, patient prognosis has been greatly improved...In addition, clinical trials of the novel TKI, ensartinib, and fourth-generation ALK-TKI for compound ALK mutation are ongoing...Studies on tissue and liquid biopsy have been reported and are expected to be useful tools for identifying resistance mechanisms. The purpose of this manuscript is to provide information on the recent clinical trials of ALK-TKIs, angiogenesis inhibitors, immune checkpoint inhibitors, and chemotherapy to describe tissue and liquid biopsy as a method to investigate the mechanisms of resistance against ALK-TKIs and suggest a proposed treatment algorithm.
- Ensacove (ensartinib) / Xcovery
Antitumor effects of ensartinib in non-small cell lung cancer harboring MET exon 14-skipping mutations (Section 32) - Mar 9, 2022 - Abstract #AACR2022AACR_5853;
These results provide the first evidence that ensartinib exhibits both preclinical and clinical antitumor activity against MET exon 14 skipping mutations with the potential of strong intracranial efficacy and warrant further evaluation in a planned phase II study thus providing more options to patients with MET exon 14 skipping mutations. Updated data including duration of response, PFS and and OS will be provided at the time of the presentation with additional few months of follow up.
- | Biomarker, Enrollment open, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Mar 9, 2022
P2, N=2316, Recruiting, Sponsor: National Cancer Institute (NCI)
Updated data including duration of response, PFS and and OS will be provided at the time of the presentation with additional few months of follow up. Suspended --> Recruiting
- Efficacy and Safety of First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_371;
10 RCTs assessing crizotinib, ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib were included and included 2,831 patients. Brigatinib was superior to crizotinib and ceritinib in PFS and intracranial ORR, and had comparable efficacy and safety profile with other 2 nd generation ALK - inhibitors in first-line treatments for patients with ALK -positive NSCLC.
- || Alecensa (alectinib) / Roche
Clinical, Review, Journal: Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. (Pubmed Central) - Feb 17, 2022
This study and literature review results showed mixed responses to alectinib in NSCLC patients who harboured rare ALK fusions. Comprehensive molecular profiling of tumour is thus strongly warranted for precise treatment strategies.
- | Ensacove (ensartinib) / Xcovery
New P2 trial: Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 15, 2022
P2, N=80, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- ||| Ensacove (ensartinib) / Xcovery
Agree as well about ALK inhibitors, but someone at these companies may eventually realize 2 prescriptions/yr for ensartinib at full price doesn't cover marketing costs & they could do far better getting meaningful fraction of market selling at 60% cost of competing agents. (Twitter) - Feb 13, 2022
- || Review, Journal: Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. (Pubmed Central) - Feb 8, 2022
Further trials are ongoing including investigation of first-line ensartinib. Next-generation inhibitors have not been compared to each other, and it is unknown which should be used first and what subsequent treatment sequence is optimal.
- || cisplatin / Generic mfg., docetaxel / Generic mfg.
Clinical, Journal: Whole-Process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report (Pubmed Central) - Feb 4, 2022
Next-generation inhibitors have not been compared to each other, and it is unknown which should be used first and what subsequent treatment sequence is optimal. The advanced ALK fusion positive lung adenocarcinoma patients, though the first-line and the second-line chemotherapy, and the follwing application of ALK-TKI treatment, has procured a total OS has reached 68 months, and the current follow-up is good.
- | Journal: Recommendations from Experts in the Management of Adverse Reactions to ALK Inhibitors (2021 Version) (Pubmed Central) - Feb 3, 2022
However, there was no guidance for the management of ALKi adverse reactions. Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions..
- ||| Ensacove (ensartinib) / Xcovery
Trial completion date: eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Jan 30, 2022
P3, N=290, Active, not recruiting, Sponsor: Xcovery Holding Company, LLC
Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.. Trial completion date: Dec 2021 --> Dec 2022